A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback